Desk
Readouts, publications and what the numbers in them do and do not show.
27 stories · latest 10 Nov 2026
The TRL desk covers results: topline announcements, peer-reviewed papers and data shown at medical meetings. Every story says which phase the trial was in, how many people took part, what the main endpoint was and whether it was met.
A company topline release is labelled as one, and a full paper is named with its journal. When a result comes from a subgroup, an observational database or an extension study, the story says so, because those designs cannot carry the same weight as the randomised comparison a trial was built around.
A medRxiv preprint from a deprived Hampshire GP practice reports the largest HbA1c falls in the six patients on insulin or GLP 1 drugs who attended four or more group sessions. Only 15 people took part, and there was no control group.
HAVANT, ENGLAND
At The Liver Meeting 2026, IMPACT trial analyses showed up to 42.9% of patients on pemvidutide met three liver test targets together at 48 weeks, against 3.3% on placebo. The results rest on noninvasive tests, and 48 week safety data were not reported.
DENVER · Poster by Alkhouri et al. at The Liver Meeting 2026, Denver, 7 Nov 2026, as reported by HCPLive on 8 Nov 2026
Lilly's placebo controlled ATTAIN-OSA program of once daily oral orforglipron in obstructive sleep apnea with obesity or overweight is a Monday late breaker at AHA. No efficacy data were public beforehand.
CHICAGO · MedPage Today AHA meeting preview, 6 Nov 2026; ATTAIN-OSA design paper (PubMed) and ClinicalTrials.gov NCT06649045
Camurus says LUNAR-2 will test its monthly semaglutide depot CAM2056 against placebo in 150 people with obesity or overweight. Its earlier data came from 80 people, and the new trial will not compare the depot with weekly injections.
LUND, SWEDEN · Camurus press release, 3 Nov 2026; Camurus Phase 1b topline release, 10 Nov 2025
A post hoc VALIANT and VALE analysis presented at Kidney Week 2026 found adolescents on pegcetacoplan kept a 67.5% drop in proteinuria at 76 weeks with stable kidney function. The long term data have no placebo comparison.
DENVER · ASN Kidney Week 2026 abstract TH-OR070 (Dixon et al.), as reported by HCPLive, 4 Nov 2026; FDA orphan drug record for approval dates
Zeus Hygia says its two week Metaberine study, which reported higher natural GLP 1 and lower glucose in 36 adults, is not weight loss evidence. The weight gap against placebo was about 0.35 kg.
HYDERABAD · International Journal of Clinical Trials paper, 28 Jul 2026; supplier comments to NutraIngredients, 2 Nov 2026
Apple Women's Health Study data presented at ASRM link combined GLP 1 and GIP drugs with cycles that shortened by 2.5 days and varied slightly less, with the largest gap in PMOS. The cohort is self reported and observational.
BALTIMORE · ASRM annual meeting presentation by Shruthi Mahalingaiah and colleagues, as reported by MedPage Today, 2 Nov 2026
Novo Nordisk will present 26 obesity abstracts in Washington from November 14 to 17, including REDEFINE 9 low dose CagriSema results and full STEP Young data in children. The announcement gives no efficacy or safety figures.
PLAINSBORO, NJ · Novo Nordisk press release via PR Newswire, 29 Oct 2026
Ascletis Pharma says its oral small molecule GLP 1 drug ASC30 lowered HbA1c by up to 1.7 points more than placebo in a 13 week U.S. Phase 2 study of 100 adults with type 2 diabetes. The data come from a press release and have not been peer reviewed.
HONG KONG · Ascletis Pharma press release via PR Newswire, 28 Oct 2026; ClinicalTrials.gov record NCT07321678
Lilly says retatrutide cut A1C by 2.2 points and weight by up to 20.9% at 80 weeks in type 2 diabetes, against 1.8 points and 9.4% on Ozempic. More people stopped retatrutide for side effects, and the data are not yet peer reviewed.
INDIANAPOLIS · Eli Lilly press release on TRANSCEND-T2D-2 topline results, 28 Oct 2026
Vanda Pharmaceuticals says its motion sickness drug Nereus lowered vomiting after a forced semaglutide dose in Phase 3, though the effect was smaller than in Phase 2 and full safety data are not public.
WASHINGTON · Vanda Pharmaceuticals press release on Study 3601, 27 Oct 2026
Two Phase 3 trials in The New England Journal of Medicine found Lilly's experimental retatrutide cut breathing pauses in 691 adults with obstructive sleep apnea, with and without type 2 diabetes. The drug is unapproved and heart outcomes were not tested.
BOSTON · The New England Journal of Medicine, Grunstein et al, TRIUMPH 1 OSA and TRIUMPH 2 OSA, DOI 10.1056/NEJMoa2611477, October 2026
At AAPS PharmSci 360, Dong-A ST reported a skin formulation of the oral psoriasis peptide icotrokinra that reached skin tissue and reduced inflammation in an animal model. No figures or human data were released.
NEW ORLEANS · Dong-A ST poster at AAPS PharmSci 360 2026, reported by Korea Biomedical Review, 27 Oct 2026; Johnson & Johnson release on Icotyde approval, 18 Mar 2026
At Kidney Week 2026, investigator Hiddo Heerspink said AstraZeneca's oral GLP 1 drug elecoglipron lowered urine albumin in a phase 2 diabetes trial. A phase 3 kidney outcomes trial with about 7,000 people is now recruiting.
DENVER · Pharmacy Times interview with Hiddo Heerspink on ASN Kidney Week 2026 data, 26 Oct 2026; ClinicalTrials.gov records NCT06579105 and NCT07753993
A retrospective study presented at EASD 2026 found that 46.3% of adults with type 2 diabetes starting tirzepatide reached HbA1c below 6.5% at 12 months, against about one in five on semaglutide, GlobalData reported.
LONDON · GlobalData analysis of a real world study presented at the EASD 2026 Annual Meeting, 14 Oct 2026, reported by Longevity.Technology on 26 Oct 2026
Lilly says the top EloraTZP pairing produced 23.3% average weight loss at 48 weeks in adults with obesity and type 2 diabetes, against 14.8% on tirzepatide alone. Dropouts for side effects were higher with the combination.
INDIANAPOLIS · Eli Lilly press release, 30 Sep 2026, on a phase 2b trial presented at EASD 2026 in Milan
A Yale led retrospective study of 60 heart failure patients with implanted pressure sensors found lower pulmonary artery pressure six months after starting semaglutide or tirzepatide, and fewer heart failure hospitalisations in the following year.
PHOENIX · Retrospective abstract presented at the HFSA Annual Scientific Meeting 2026, Phoenix, 9 to 12 Oct 2026, as reported by HCPLive on 11 Oct 2026
In a Novo Nordisk funded real world analysis of 194 adults who moved from weekly injections to the daily Wegovy pill, average weight fell another 4.1% over three months. The study had no control group and relied on telehealth records.
MILAN · Novo Nordisk press release, 30 Sep 2026, on the OCTANE analysis presented at EASD 2026 (LBA 59)
In the ZUPREME 1 phase 2 study, weekly petrelintide cut body weight by up to 9.8% at 28 weeks against 1.7% on placebo. Nausea was the most common side effect, and the drug was never tested against a GLP 1 medicine.
COPENHAGEN · The Lancet Diabetes and Endocrinology, ZUPREME 1 phase 2 trial report and linked comment, published online 29 Sep 2026
An analysis of the TOGETHER trials found that adding tirzepatide to ixekizumab cut predicted 10 year cardiovascular risk by about 30% at week 36 in people with psoriatic disease and obesity. The figure is a risk score, not counted heart attacks.
VIENNA · EADV Congress 2026 abstract 4328 (Weber et al.), as reported by Healio on 21 Oct 2026; TOGETHER-PsO and TOGETHER-PsA phase 3b trials
The KRAS peptide vaccine from Elicio Therapeutics did not significantly extend disease free survival in AMPLIFY-7P, Nature Medicine reports. Strong T cell responders did better, a signal the company plans to use in designing a phase 3 trial.
BOSTON · Nature Medicine, AMPLIFY-7P randomised phase 2 trial report, published online 23 Oct 2026
Adults with type 1 diabetes and obesity who stopped semaglutide after the ADJUST-T1D trial lost a median 3.6 points of time in range within 12 weeks, a small post hoc study reports.
PHILADELPHIA · Diabetes, Obesity and Metabolism, ADJUST-T1D extension study, online 31 Aug 2026; presented at Breakthrough T1D congress, 9 to 11 Oct 2026
Lilly's triple-hormone peptide, acting on GIP, GLP-1 and glucagon receptors, also eased knee pain in people with obesity and knee osteoarthritis.
INDIANAPOLIS · Eli Lilly announcement (TRIUMPH-4 topline)
Oral semaglutide did not slow the progression of early Alzheimer's disease compared with placebo, ending one of the most watched tests of GLP-1 drugs outside metabolism.
BAGSVÆRD, Denmark · Novo Nordisk company announcement (EVOKE and EVOKE+ topline)
Orforglipron hits the GLP-1 receptor without being a peptide at all. Its first phase 3 obesity result was solid but below the injectable peptides, and that gap is the story.
INDIANAPOLIS · Eli Lilly announcement (ATTAIN-1 topline)
The first randomised comparison of the two best-selling obesity peptides found more weight loss and a larger drop in waist size with tirzepatide.
MÁLAGA, Spain · SURMOUNT-5 (NEJM); European Congress on Obesity 2025
The amylin plus semaglutide combination produced large weight loss in REDEFINE 1, but fell short of the figure the company had signalled to investors.
BAGSVÆRD, Denmark · Novo Nordisk company announcement (REDEFINE 1 topline)
